Go to main content

Basal Insulin

A woman injects insulin

Lilly’s Once-Weekly Insulin Delivers Similar A1C Reduction to Daily Basal Insulin

French-based pharma company Sanofi confirmed the construction of a brand-new $1.4 billion insulin manufacturing facility in Germany, expected to be completed in 2029.

Sanofi to Build New State-of-the-Art Insulin Plant

Learn how combination drugs like Soliqua and Xultophy can help manage type 2 diabetes

6 Benefits of Combining Insulin and GLP-1 Drugs

Long-Acting Basaglar and the New Era of “Biosimilar” Insulin

What you need to know about the new insulin, its cost, dosing, and beyond!

Xultophy Beats Out Lantus in Major Clinical Trial

One of the biggest drug highlights at the 2015 ADA Scientific Sessions was a compelling presentation by diaTribe scientific Advisory Board member Dr. John Buse on brand new phase 3 clinical trial data comparing Xultophy (a GLP-1 agonist/long acting insulin combination taken as a single injection) to Lantus (a long acting insulin) for the treatment of type 2 diabetes. The results of the 26-week study were very impressive...

FDA Approves Ultra-Long-Acting Basal Insulin Tresiba – Take It At Any Time of Day!

Gamechanging Xultophy (Tresiba + Victoza) also now submitted to the FDA.